Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck

• DOI: 10.1002/hed.23577
• Publication Date: 2013-12-18T02:46:50Z
• Authors: David J. Thomson; Priyamal Silva; Kim Denton; Suzanne Bonington; Soo K. Mak; Ric Swindell; Jarrod Homer; Andrew J. Sykes; Lip W. Lee; Beng K. Yap; Nicholas J. Slevin
• Keywords: Adenoid Cystic Carcinoma; Progression-free survival

Abstract Background There is a need to improve the systemic treatment of advanced adenoid cystic carcinoma (ACC). Response rates chemotherapy are poor and preliminary investigations molecularly targeted agents have been disappointing. In this study, we evaluate sorafenib, an oral multikinase inhibitor, which has attractive targeting profile for disease. Methods single‐arm phase II trial, patients with unresectable locally recurrent and/or metastatic ACC were treated sorafenib 400 mg bid. Results Twenty‐three patients, median age 51 years, recruited from 2009 2011. Median progression‐free survival (PFS) overall (OS) 11.3 19.6 months, respectively. PFS at 6 12 months 69.3% 46.2%, Sorafenib was only reasonably well tolerated, 13 (57%) experienced grade 3 toxicity. Conclusion showed modest activity in 12‐month 46.2%. bid associated significant toxicity and, taken together limited effectiveness, cannot be enthusiastically recommended further evaluation. © 2014 Wiley Periodicals, Inc. Head Neck 37 : 182‐187, 2015